children septic shock
Conditions
Interventions
Phase I low dose group:Human umbilical cord derived mesenchymal stem cells (UC - MSCs)
Phase I moderate dose grou:Human umbilical cord derived mesenchymal stem cells (HU - MSCs)
Phase I high dose group:Human umbilical cord derived mesenchymal stem cells (HU - MSCs)
Phase II control group: Human umbilical cord derived mesenchymal stem cells (HU - MSCs)
Sponsors
Daping hospital, Army medical university
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. TGood adherence to patients and their families with informed consents 2. PICU inpatients aged = 28d, 2 s, weak pulse, wet end of limbs; or capillary flash refilling, flood veins and pulse pressure widening; or urine volume 7 days
Exclusion criteria
Exclusion criteria: 1. Patients with the following diseases: bone marrow, lung, liver, kidney and other transplant history, genetic metabolic diseases; 2. The patient has a history of allergies to biological products, hypersensitivity reactions or other serious reactions; 3. The patient is in a predictable dying state; 4. Suffering from chromosomal abnormalities (such as 18-trisomy, 13-trisomy or 21-trisomy) or severe congenital malformations (such as hydrocephalus and brain swelling, tracheoesophageal fistula, abdominal wall defects and major renal abnormalities); 5. Surgery is expected within 72 hours before or after study drug administration; 6. History of malignant tumors in the past 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| paediatric index of mortality, PIM; | — |
Countries
China
Contacts
Public ContactXiang Xu
Research Institute of Surgery, Daping Hospital, Army Medical University
Outcome results
None listed